Soybean Oil
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Soybean Oil: From Parenteral Nutrition Lipid Source to Amenorrhea
One-Sentence Summary
Soybean oil is marketed in Canada mainly as a lipid component of parenteral nutrition products, where it supplies calories and essential fatty acids. The TxGNN model predicts it may be effective for amenorrhea, but there are currently no clinical trials and no publications supporting this direction, so the prediction rests on the computational model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the Health Canada licence data (the products are used as parenteral lipid emulsions) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 0.9961 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 13 of 13) |
| Number of DINs | 13 (marketed: 13) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, soybean oil is a marketed lipid source used in parenteral nutrition emulsions and as a dietary oil. No established mechanistic link to amenorrhea has been identified.
The TxGNN score (0.9961) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not backed by any clinical or literature evidence in the data compiled for this report. Soybean oil is not a recognised treatment for amenorrhea.
Some speculative, indirect pathways can be imagined:
- Energy deficit or malnutrition: Functional hypothalamic amenorrhea is linked to low energy availability, and long-term parenteral nutrition addresses malnutrition. Any benefit would come from correcting nutritional status, not from a direct effect on menstrual function.
- Essential fatty acid deficiency: Soybean oil supplies essential fatty acids, which could matter if a deficiency is contributing.
- Phytoestrogen or lipid-mediated effects: These could in theory influence the hypothalamic-pituitary-ovarian axis.
None of these pathways is supported by data here, and they should be treated as hypotheses only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Health Canada lists 13 valid licences. The data compiled for this report do not include dosage forms or approved indication text for these products. The main ones are:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02065673 | INTRALIPID 20% | Not available | Not available |
| 02344327 | CLINOLEIC 20% | Not available | Not available |
| 02396963 | SMOFLIPID 20% | Not available | Not available |
| 02352540 | OLIMEL 5.7% | Not available | Not available |
| 02477947 | OLIMEL 7.6% | Not available | Not available |
The remaining licences are SMOFKABIVEN variants (Electrolyte Free, Extra Nitrogen, Extra Nitrogen Electrolyte Free, Peripheral, standard), PERIOLIMEL 2.5% E, OLIMEL 5.7% E and OLIMEL 7.6% E.
Safety Considerations
Please refer to the package insert for safety information. No drug-drug interaction records were found, and no contraindication data were identified for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials, no literature and no plausible direct mechanism. Soybean oil is also not a recognised treatment for amenorrhea. The package insert warnings and contraindications have not been reviewed, so safety screening cannot proceed.
To proceed, the following is needed:
- Health Canada package insert warnings, contraindications and approved indications (download and parse the product monographs)
- Mechanism of action data (for example, from DrugBank)
- A systematic literature and trial search on lipid emulsions or essential fatty acids in amenorrhea, particularly functional hypothalamic amenorrhea and parenteral nutrition populations
- Assessment of route compatibility, since the licensed products are all intravenous lipid emulsions
- Mechanistic and preclinical support before any clinical consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.